X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SUVEN LIFE - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SUVEN LIFE ASTRAZENECA PHARMA/
SUVEN LIFE
 
P/E (TTM) x 120.7 14.1 853.1% View Chart
P/BV x 17.2 3.4 511.6% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ASTRAZENECA PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
SUVEN LIFE
Mar-17
ASTRAZENECA PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs1,285229 562.4%   
Low Rs634151 419.6%   
Sales per share (Unadj.) Rs189.642.7 444.0%  
Earnings per share (Unadj.) Rs-0.26.9 -3.0%  
Cash flow per share (Unadj.) Rs3.88.5 45.1%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs68.652.4 131.0%  
Shares outstanding (eoy) m25.00127.28 19.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.14.4 113.9%   
Avg P/E ratio x-4,712.727.7 -17,008.4%  
P/CF ratio (eoy) x249.622.2 1,122.0%  
Price / Book Value ratio x14.03.6 386.0%  
Dividend payout %014.6 0.0%   
Avg Mkt Cap Rs m23,98824,158 99.3%   
No. of employees `0001.61.0 153.4%   
Total wages/salary Rs m1,605522 307.6%   
Avg. sales/employee Rs Th3,040.25,349.7 56.8%   
Avg. wages/employee Rs Th1,029.2513.5 200.4%   
Avg. net profit/employee Rs Th-3.3858.1 -0.4%   
INCOME DATA
Net Sales Rs m4,7405,435 87.2%  
Other income Rs m92211 43.7%   
Total revenues Rs m4,8325,646 85.6%   
Gross profit Rs m-1301,291 -10.1%  
Depreciation Rs m101214 47.3%   
Interest Rs m057 0.0%   
Profit before tax Rs m-1391,231 -11.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5359 1.4%   
Profit after tax Rs m-5872 -0.6%  
Gross profit margin %-2.723.7 -11.5%  
Effective tax rate %-3.729.2 -12.6%   
Net profit margin %-0.116.0 -0.7%  
BALANCE SHEET DATA
Current assets Rs m2,7264,917 55.4%   
Current liabilities Rs m2,4351,186 205.3%   
Net working cap to sales %6.168.6 9.0%  
Current ratio x1.14.1 27.0%  
Inventory Days Days7462 118.7%  
Debtors Days Days4131 132.4%  
Net fixed assets Rs m1,0353,154 32.8%   
Share capital Rs m50127 39.3%   
"Free" reserves Rs m9426,543 14.4%   
Net worth Rs m1,7166,670 25.7%   
Long term debt Rs m0259 0.0%   
Total assets Rs m4,1568,157 50.9%  
Interest coverage xNM22.7-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.10.7 171.2%   
Return on assets %-0.111.4 -1.1%  
Return on equity %-0.313.1 -2.3%  
Return on capital %018.6 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m3754,996 7.5%   
Fx outflow Rs m470959 49.0%   
Net fx Rs m-964,037 -2.4%   
CASH FLOW
From Operations Rs m-81,088 -0.7%  
From Investments Rs m-146-3,107 4.7%  
From Financial Activity Rs m862-300 -287.2%  
Net Cashflow Rs m709-2,319 -30.6%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 15.7 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 36.5 24.9%  
Shareholders   12,856 37,287 34.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PLETHICO PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; SBI Up 3.7%(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


May 23, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS